BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget 2017;8:77734-51. [PMID: 29100421 DOI: 10.18632/oncotarget.20774] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Zeng Z, Cao Z, Tang Y. Increased E2F2 predicts poor prognosis in patients with HCC based on TCGA data. BMC Cancer 2020;20:1037. [PMID: 33115417 DOI: 10.1186/s12885-020-07529-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Wang H, Wang X, Xu L, Zhang J, Cao H. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets. Purinergic Signal 2020;16:347-66. [PMID: 32638267 DOI: 10.1007/s11302-020-09711-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhu Z, Li L, Xu J, Ye W, Chen B, Zeng J, Huang Z. Comprehensive analysis reveals a metabolic ten-gene signature in hepatocellular carcinoma. PeerJ 2020;8:e9201. [PMID: 32518728 DOI: 10.7717/peerj.9201] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Fu Z, Jiao Y, Li Y, Ji B, Jia B, Liu B. TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer. Medicine (Baltimore) 2019;98:e18487. [PMID: 31861032 DOI: 10.1097/MD.0000000000018487] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
5 Zhang D, Liu J, Xie T, Jiang Q, Ding L, Zhu J, Ye Q. Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma. Int J Biol Sci 2020;16:2812-27. [PMID: 33061798 DOI: 10.7150/ijbs.49785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Guo Y, Luo W, Huang S, Zhao W, Chen H, Ma Y, Ye M, Nie Y, Zhang Y, Huang C, Zhou Q, He X, Chen M. DTYMK Expression Predicts Prognosis and Chemotherapeutic Response and Correlates with Immune Infiltration in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:871-85. [PMID: 34377684 DOI: 10.2147/JHC.S312604] [Reference Citation Analysis]
7 Cao Y, Lu X, Li Y, Fu J, Li H, Li X, Chang Z, Liu S. Identification of a six-gene metabolic signature predicting overall survival for patients with lung adenocarcinoma. PeerJ 2020;8:e10320. [PMID: 33344071 DOI: 10.7717/peerj.10320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacological Research 2019;139:298-313. [DOI: 10.1016/j.phrs.2018.11.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
9 Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Tsunekuni K, Konno M, Haraguchi N, Koseki J, Asai A, Matsuoka K, Kobunai T, Takechi T, Doki Y, Mori M, Ishii H. CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure. Sci Rep 2019;9:14861. [PMID: 31619711 DOI: 10.1038/s41598-019-50968-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
11 Chen CT, Lee HL, Chiou HL, Chou CH, Wang PH, Yang SF, Chou YE. Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development. PLoS One 2018;13:e0198967. [PMID: 29889892 DOI: 10.1371/journal.pone.0198967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 He G, Qiu J, Liu C, Tian B, Cai D, Liu S. MiR-148b-3p Regulates the Expression of DTYMK to Drive Hepatocellular Carcinoma Cell Proliferation and Metastasis. Front Oncol 2021;11:625566. [PMID: 35004265 DOI: 10.3389/fonc.2021.625566] [Reference Citation Analysis]
13 Wu Z, Tan J, Zhuang Y, Zhong M, Xiong Y, Ma J, Yang Y, Gao Z, Zhao J, Ye Z, Zhou H, Zhu Y, Lu H, Hong X. Identification of crucial genes of pyrimidine metabolism as biomarkers for gastric cancer prognosis. Cancer Cell Int 2021;21:668. [PMID: 34906153 DOI: 10.1186/s12935-021-02385-x] [Reference Citation Analysis]
14 Wang D, Liu J, Liu S, Li W. Identification of Crucial Genes Associated With Immune Cell Infiltration in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis. Front Genet 2020;11:342. [PMID: 32391055 DOI: 10.3389/fgene.2020.00342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
15 Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748-66. [PMID: 31666728 DOI: 10.1038/s41575-019-0217-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
16 Zeng Z, Jiang X, Pan Z, Zhou R, Lin Z, Tang Y, Cui Y, Zhang E, Cao Z. Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:22802-29. [PMID: 34607313 DOI: 10.18632/aging.203574] [Reference Citation Analysis]
17 Kwan SY, Sheel A, Song CQ, Zhang XO, Jiang T, Dang H, Cao Y, Ozata DM, Mou H, Yin H, Weng Z, Wang XW, Xue W. Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes. Hepatology 2020;71:275-90. [PMID: 31188495 DOI: 10.1002/hep.30807] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
18 Zhou T, Qin R, Shi S, Zhang H, Niu C, Ju G, Miao S. DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle. Cell Cycle 2021;:1-11. [PMID: 34369850 DOI: 10.1080/15384101.2021.1958502] [Reference Citation Analysis]
19 Cui L, Xue H, Wen Z, Lu Z, Liu Y, Zhang Y. Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. Aging (Albany NY) 2020;12:22199-219. [PMID: 33188160 DOI: 10.18632/aging.104122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]